British start-up Exscientia and Japanese pharmaceutical firm Sumitomo Dainippon Pharma have created a drug molecule to treat Obsessive compulsive disorder using Artificial Intelligence.  The precisely engineered drug will enter phase one trials in Japan which, if successful, will be followed by more global tests. The firm is working on potential drugs for the treatment of […]